Vincent L Cryns

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7350671/publications.pdf

Version: 2024-02-01

45 papers	3,287 citations	249298 26 h-index	286692 43 g-index
47 all docs	47 docs citations	47 times ranked	5386 citing authors

#	Article	IF	Citations
1	A p53â€“phosphoinositide signalosome regulates nuclear AKT activation. Nature Cell Biology, 2022, 24, 1099-1113.	4.6	26
2	Assessing In Situ Phosphoinositideâ€“Protein Interactions Through Fluorescence Proximity Ligation Assay in Cultured Cells. Methods in Molecular Biology, 2021, 2251, 133-142.	0.4	6
3	Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase. Breast Cancer Research and Treatment, 2021, 190, 373-387.	1.1	11
4	The nuclear phosphoinositide response to stress. Cell Cycle, 2020, 19, 268-289.	1.3	22
5	Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells. Breast Cancer Research and Treatment, 2020, 183, 549-564.	1.1	24
6	Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin. Molecular Cancer Therapeutics, 2020, 19, 2278-2287.	1.9	10
7	Ionizing Radiation-induced Proteomic Oxidation in Escherichia coli. Molecular and Cellular Proteomics, 2020, 19, 1375-1395.	2.5	26
8	Methyl-Metabolite Depletion Elicits Adaptive Responses to Support Heterochromatin Stability and Epigenetic Persistence. Molecular Cell, 2020, 78, 210-223.e8.	4.5	45
9	Self-Assembled Peptide Nanostructures Targeting Death Receptor 5 and Encapsulating Paclitaxel As a Multifunctional Cancer Therapy. ACS Biomaterials Science and Engineering, 2019, 5, 6046-6053.	2.6	19
10	S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells. Breast Cancer Research and Treatment, 2019, 175, 39-50.	1.1	55
11	A nuclear phosphoinositide kinase complex regulates p53. Nature Cell Biology, 2019, 21, 462-475.	4.6	57
12	Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction. Methods in Molecular Biology, 2019, 1866, 61-73.	0.4	5
13	Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. Asian Journal of Urology, 2019, 6, 57-64.	0.5	15
14	Methionine restriction activates the integrated stress response in triple-negative breast cancer cells by a GCN2- and PERK-independent mechanism. American Journal of Cancer Research, 2019, 9, 1766-1775.	1.4	6
15	Aberrant expression of glycogen synthase kinaseâ€“3Î² in human breast and head and neck cancer. Oncology Letters, 2018, 16, 6437-6444.	0.8	14
16	Shortâ€term methionine deprivation improves metabolic health via sexually dimorphic, mTORCIâ€independent mechanisms. FASEB Journal, 2018, 32, 3471-3482.	0.2	73
17	Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. Journal of Urology, 2018, 200, 1256-1263.	0.2	42
18	The effects of sex and age on the metabolic response to methionine deprivation, a novel intervention for the treatment of obesity and diabetes. FASEB Journal, 2018, 32, 925.3.	0.2	0

#	Article	IF	Citations
19	Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression. Breast Cancer Research and Treatment, 2017, 163, 435-447.	1.1	27
20	Hypocalciuria as a Predictor of Reduced Intestinal Calcium Absorption. Journal of the Endocrine Society, 2017, 1, 1179-1187.	0.1	2
21	GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Letters, 2016, 380, 384-392.	3.2	55
22	Î±B-crystallin and HspB2 deficiency is protective from diet-induced glucose intolerance. Genomics Data, 2016, 9, 10-17.	1.3	3
23	Î±B-crystallin: Portrait of a malignant chaperone as a cancer therapeutic target. , 2016, 160, 1-10.		35
24	Î±B-crystallin expression in breast cancer is associated with brain metastasis. Npj Breast Cancer, 2015, 1, .	2.3	30
25	Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression. Clinical Cancer Research, 2015, 21, 2780-2791.	3.2	77
26	pH and Amphiphilic Structure Direct Supramolecular Behavior in Biofunctional Assemblies. Journal of the American Chemical Society, 2014, 136, 14746-14752.	6.6	161
27	NanoFlares for the detection, isolation, and culture of live tumor cells from human blood. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17104-17109.	3.3	197
28	Î±B-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain. Clinical Cancer Research, 2014, 20, 56-67.	3.2	87
29	Î±B-Crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation. Breast Cancer Research and Treatment, 2013, 138, 415-425.	1.1	14
30	Coassembled Cytotoxic and Pegylated Peptide Amphiphiles Form Filamentous Nanostructures with Potent Antitumor Activity in Models of Breast Cancer. ACS Nano, 2012, 6, 7956-7965.	7.3	90
31	Antitumor Activity of Peptide Amphiphile Nanofiber-Encapsulated Camptothecin. ACS Nano, 2011, 5, 9113-9121.	7.3	219
32	Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies. Molecular Endocrinology, 2011, 25, 199-211.	3.7	138
33	Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer. Clinical Cancer Research, 2011, 17, 5005-5015.	3.2	43
34	Induction of Cancer Cell Death by Self-assembling Nanostructures Incorporating a Cytotoxic Peptide. Cancer Research, 2010, 70, 3020-3026.	0.4	182
35	Regulation of Î±B-crystallin gene expression by the transcription factor Ets1 in breast cancer. Breast Cancer Research and Treatment, 2010, 119, 63-70.	1.1	26
36	Induction of the small heat shock protein Î±B-crystallin by genotoxic stress is mediated by p53 and p73. Breast Cancer Research and Treatment, 2010, 122, 159-168.	1.1	12

#	Article	IF	Citations
37	Î±B-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2008, 111, 411-417.	1.1	60
38	Aspirin Sensitizes Cancer Cells to TRAILâ€“Induced Apoptosis by Reducing Survivin Levels. Clinical Cancer Research, 2008, 14, 3168-3176.	3.2	68
39	Î±B-crystallin: A novel marker of invasive basal-like and metaplastic breast carcinomas. Annals of Diagnostic Pathology, 2008, 12, 33-40.	0.6	61
40	Deconstructing the molecular portrait of basal-like breast cancer. Trends in Molecular Medicine, 2006, 12, 537-544.	3.5	132
41	The Small Heat Shock Protein Î±B-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3. Journal of Biological Chemistry, 2005, 280, 11059-11066.	1.6	196
42	Peroxisome Proliferator-activated Receptor Î³ Agonists Promote TRAIL-induced Apoptosis by Reducing Survivin Levels via Cyclin D3 Repression and Cell Cycle Arrest. Journal of Biological Chemistry, 2005, 280, 6742-6751.	1.6	98
43	ÂB-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. Journal of Clinical Investigation, 2005, 116, 261-270.	3.9	256
44	The Small Heat Shock Protein Î±B-crystallin Negatively Regulates Apoptosis during Myogenic Differentiation by Inhibiting Caspase-3 Activation. Journal of Biological Chemistry, 2002, 277, 38731-38736.	1.6	237
45	The Small Heat Shock Protein Î±B-Crystallin Negatively Regulates Cytochrome c- and Caspase-8-dependent Activation of Caspase-3 by Inhibiting Its Autoproteolytic Maturation. Journal of Biological Chemistry, 2001, 276, 16059-16063.	1.6	324